Regenxbio
Regenxbio
RGNX
NASDAQ
12.22
USD
62.72%
About
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases.
The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision.
It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 320.8K |
| Three Month Average Volume | 11.8M |
| High Low | |
| Fifty-Two Week High | 28.8 USD |
| Fifty-Two Week Low | 10.49 USD |
| Fifty-Two Week High Date | 05 Mar 2024 |
| Fifty-Two Week Low Date | 08 Jul 2024 |
| Price and Volume | |
| Current Price | 12.22 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -11.30% |
| Thirteen Week Relative Price Change | -20.43% |
| Twenty-Six Week Relative Price Change | -47.55% |
| Fifty-Two Week Relative Price Change | -44.90% |
| Year-to-Date Relative Price Change | -42.51% |
| Price Change | |
| One Day Price Change | 1.83% |
| Thirteen Week Price Change | -14.84% |
| Twenty-Six Week Price Change | -42.33% |
| Five Day Price Change | 0.74% |
| Fifty-Two Week Price Change | -30.96% |
| Year-to-Date Price Change | -31.92% |
| Month-to-Date Price Change | -14.25% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 7.07765 USD |
| Book Value Per Share (Most Recent Quarter) | 7.0618 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 7.07765 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 7.0618 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -4.98633 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 2.06343 USD |
| Revenue Per Share (Trailing Twelve Months) | 1.93277 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -6.02492 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -5.26899 USD |
| Normalized (Last Fiscal Year) | -6.02492 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -6.02492 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -5.26899 USD |
| Including Extraordinary Items (Last Fiscal Year) | -6.02492 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -5.26899 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 6.24933 USD |
| Cash Per Share (Most Recent Quarter) | 5.88756 USD |
| Cash Flow Per Share (Last Fiscal Year) | -5.62889 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -4.86508 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -4.22643 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -62 |
| Cash Flow Revenue (Trailing Twelve Months) | -219 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -270.91% |
| Pretax Margin (Last Fiscal Year) | -292.15% |
| Pretax Margin (5 Year) | -70.25% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 58.76% |
| Gross Margin (Trailing Twelve Months) | 56.78% |
| Gross Margin (5 Year) | 78.27% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -297.12% |
| Operating Margin (Trailing Twelve Months) | -279.37% |
| Operating Margin (5 Year) | -74.06% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -291.99% |
| Net Profit Margin (Trailing Twelve Months) | -270.74% |
| Net Profit Margin (5 Year) | -72.06% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -12.86% |
| Tangible Book Value (5 Year) | -9.33% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 11.60% |
| Revenue Growth (3 Year) | -16.21% |
| Revenue Change (Trailing Twelve Months) | -8.18% |
| Revenue Per Share Growth | -19.12% |
| Revenue Growth (5 Year) | -16.42% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -5.59% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 36.74% |
| EPS Change (Trailing Twelve Months) | 16.62% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -290,357,000 |
| Net Debt (Last Fiscal Year) | -275,258,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 7 |
| Price to Sales (Trailing Twelve Months) | 7 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 29 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 15 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 3 |
| Current Ratio (Most Recent Quarter) | 4 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -228,367,000 |
| Free Cash Flow (Trailing Twelve Months) | -194,715,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -37.45% |
| Return on Assets (Trailing Twelve Months) | -38.52% |
| Return on Assets (5 Year) | -16.75% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -63.65% |
| Return on Equity (Trailing Twelve Months) | -63.94% |
| Return on Equity (5 Year) | -24.69% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -45.96% |
| Return on Investment (Trailing Twelve Months) | -46.55% |
| Return on Investment (5 Year) | -19.08% |